Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

COPENHAGEN BIOTECH SUPPLY ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Bankruptcy risk for industry   1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%   Bankruptcy risk   4.4% 3.6% 2.6% 2.6% 2.0% 1.5% 10.9% 10.9%   Credit score (0-100)   49 53 61 60 69 74 22 22   Credit rating   BBB BBB BBB BBB A A BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.3 6.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,076 977 1,581 1,490 1,800 1,897 0.0 0.0   EBITDA   62.5 74.6 523 600 663 722 0.0 0.0   EBIT   62.5 74.6 523 600 663 722 0.0 0.0   Pre-tax profit (PTP)   62.4 74.6 519.3 595.5 661.8 721.9 0.0 0.0   Net earnings   48.4 58.6 399.3 460.5 509.8 564.9 0.0 0.0   Pre-tax profit without non-rec. items   62.4 74.6 519 596 662 722 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   229 287 526 637 797 862 615 615   Interest-bearing liabilities   4.9 5.7 11.5 6.2 464 613 0.0 0.0   Balance sheet total (assets)   788 957 1,301 1,576 2,412 2,016 615 615   Net Debt   -340 -399 -619 -842 -184 -508 -615 -615     See the entire balance sheet 1000.0 Volume  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,076 977 1,581 1,490 1,800 1,897 0.0 0.0   Gross profit growth   12.8% -9.3% 61.9% -5.8% 20.8% 5.4% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   788 957 1,301 1,576 2,412 2,016 615 615   Balance sheet change%   -3.9% 21.5% 35.9% 21.2% 53.0% -16.4% -69.5% 0.0%   Added value   62.5 74.6 523.1 599.6 663.3 721.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   5.8% 7.6% 33.1% 40.2% 36.9% 38.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   7.8% 8.5% 46.3% 41.7% 33.3% 32.6% 0.0% 0.0%   ROI %   24.1% 28.3% 125.9% 101.5% 69.7% 52.8% 0.0% 0.0%   ROE %   19.0% 22.7% 98.1% 79.2% 71.1% 68.1% 0.0% 0.0%   1000.0 Solidity  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Equity ratio %   29.0% 30.0% 40.5% 40.4% 33.0% 42.7% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -544.4% -534.7% -118.3% -140.4% -27.7% -70.4% 0.0% 0.0%   Gearing %   2.1% 2.0% 2.2% 1.0% 58.2% 71.2% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   2.5% 0.0% 44.5% 46.5% 0.7% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Quick Ratio   1.2 1.1 1.4 1.6 1.1 1.5 0.0 0.0   Current Ratio   1.4 1.4 1.7 1.7 1.5 1.7 0.0 0.0   Cash and cash equivalent   345.2 404.4 630.2 848.0 647.2 1,121.6 0.0 0.0   1000.0 Capital use efficiency  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   228.6 287.2 526.5 637.0 796.7 861.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   63 75 523 600 663 722 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   63 75 523 600 663 722 0 0   EBIT / employee   63 75 523 600 663 722 0 0   Net earnings / employee   48 59 399 461 510 565 0 0